Mohamed ElRefai
Overview
Explore the profile of Mohamed ElRefai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
38
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
ElRefai M, Menexi C, Roberts P
J Innov Card Rhythm Manag
. 2024 Nov;
15(11):6088-6094.
PMID: 39563989
Sarcoidosis is a complex disease characterized by inflammatory granulomas that can affect various organs, including the heart. The diagnosis of cardiac sarcoidosis poses challenges, and current criteria involve the use...
2.
Wormann J, Strik M, Jurisic S, Stout K, ElRefai M, Becher N, et al.
Europace
. 2024 Jun;
26(7).
PMID: 38885309
Aims: Subcutaneous implantable cardioverter-defibrillators (S-ICDs) have become established in preventing sudden cardiac death, with some advantages over transvenous defibrillator systems, including a lower incidence of lead failures. Despite technological advancements,...
3.
ElRefai M, Abouelasaad M, Conibear I, Wiles B, Dunn A, Coniglio S, et al.
Indian Pacing Electrophysiol J
. 2024 Jun;
24(4):192-199.
PMID: 38871179
Introduction: The risk of complications associated with transvenous ICDs make the subcutaneous implantable cardiac defibrillator (S-ICD) a valuable alternative in patients with adult congenital heart disease (ACHD). However, higher S-ICD...
4.
Wormann J, Strik M, Jurisic S, Stout K, ElRefai M, Becher N, et al.
Europace
. 2024 Jun;
26(6).
PMID: 38861398
Aims: Subcutaneous implantable cardioverter-defibrillators (S-ICDs) offer potentially distinct advantages over transvenous defibrillator systems. Recent randomized trials showed significantly lower lead failure rates than transvenous ICD. Still, S-ICDs remain associated with...
5.
6.
Menexi C, ElRefai M, Abouelasaad M, Chua A, Handa I, Newbery C, et al.
Pacing Clin Electrophysiol
. 2024 Jan;
47(2):195-202.
PMID: 38214035
Background: Peri-procedural complications associated with cardiac implantable electronic devices are not uncommon. European Society of Cardiology guidelines recommend device checks of all devices within 72 h of implant. European Heart...
7.
Menexi C, ElRefai M, Farwell D, Srinivasan N
Indian Pacing Electrophysiol J
. 2023 Dec;
24(2):94-104.
PMID: 38159808
We present the case of a 16-year-old male pediatric patient diagnosed with hypertrophic cardiomyopathy (HCM, identified as having a high risk of sudden cardiac death (SCD), who underwent a successful...
8.
ElRefai M, Menexi C, Abouelasaad M, Roberts P
Br J Radiol
. 2023 May;
96(1150):20220788.
PMID: 37171811
Objective: Leadless pacemakers (LPs) were designed to avoid complications associated with transvenous pacing. To minimise risk of perforations, there is preference towards implanting LPs into the septum rather than the...
9.
ElRefai M, Abouelasaad M, Wiles B, Dunn A, Coniglio S, Zemkoho A, et al.
Ann Noninvasive Electrocardiol
. 2023 Mar;
28(4):e13056.
PMID: 36920649
Background: Machine learning methods are used in the classification of various cardiovascular diseases through ECG data analysis. The concept of varying subcutaneous implantable cardiac defibrillator (S-ICD) eligibility, owing to the...
10.
ElRefai M, Menexi C, Abouelasaad M, Tsoi V, Roberts P
J Interv Card Electrophysiol
. 2022 Dec;
PMID: 36525169
No abstract available.